The Drug Shortages That Keep Happening and Nobody Fixes

Every so often, a story surfaces that a hospital has run out of a common medicine — a basic chemotherapy drug, a sterile injectable, an antibiotic that has existed for decades — and doctors are rationing what remains or improvising alternatives. The story flares, provokes brief alarm, and fades. Then, months later, it happens again, with a different drug, in a different place, and the same expressions of surprise. But there is nothing surprising about it. Drug shortages are not random misfortunes; they are the predictable output of a system whose incentives are pointed in exactly the wrong direction. Understanding why they persist reveals a market failure hiding in plain sight, one that recurs precisely because no one whose job it is to fix it has sufficient reason to.

A crisis that targets the cheapest drugs

The first counterintuitive fact about drug shortages is which drugs they affect. It is not the expensive, cutting-edge medicines that run out; those are profitable, and profitable products attract reliable supply. The drugs that vanish are overwhelmingly the old, cheap, generic ones — the sterile injectables, the basic chemotherapy agents, the essential hospital medicines that have been off-patent for years and cost very little. These are among the most important drugs in medicine, the ones without which routine treatment becomes impossible, and they are the ones the system most reliably fails to keep in stock.

This pattern is the key to the whole phenomenon, because it points directly at the cause. A shortage that struck randomly, or that hit expensive and cheap drugs alike, would suggest bad luck or logistical difficulty. A shortage that concentrates, again and again, on the least profitable products suggests something structural: that the problem is not difficulty of manufacture but a lack of incentive to manufacture reliably. The drugs that disappear are precisely the ones where there is little money to be made, and that correlation is not a coincidence. It is the mechanism.

The economics that guarantee failure

To see why cheap generics keep failing, follow the money through the supply chain. Once a drug goes off-patent, competition drives its price down toward the cost of production, which is good for buyers but brutal for manufacturers, whose margins on these products become razor-thin or vanish. With so little profit in each unit, manufacturers have scant incentive to invest in the resilient, redundant production capacity that would prevent shortages — the extra facilities, the quality upgrades, the buffer stock. Reliability costs money, and there is no money in these drugs to pay for it.

The result is a supply chain stretched to its thinnest and most fragile point. Production of a given essential generic may be concentrated in a very small number of facilities, sometimes a single one, because no manufacturer can justify building redundancy for a product that barely breaks even. When something goes wrong at one of those facilities — a quality problem, a contamination issue, a shutdown — there is no slack in the system to absorb it, and a shortage follows immediately. The economics that make these drugs cheap are the same economics that make them fragile. The market has optimised the price to the bone and, in doing so, optimised away the resilience. This is the same logic, running in a different sector, that governs so many systems where cost-cutting quietly erodes the capacity to withstand shocks — a pattern visible too in the strained conditions of high-throughput operations elsewhere in the economy.

The fragility no one is paid to fix

What makes drug shortages so intractable is that no single actor in the system has both the ability and the incentive to solve them. Manufacturers cannot justify investing in resilience for products that lose money; doing so would be a gift to competitors and a hit to their own balance sheet. Purchasers — hospitals and the group buyers that negotiate on their behalf — have driven prices down precisely as they were meant to, and the low prices they achieved are part of what starved the supply chain of the margin needed for reliability. Everyone in the chain is behaving rationally within their own incentives, and the collective result is a system that predictably fails.

This is the defining feature of the crisis and the reason it recurs. It is not a problem of villainy or incompetence but of structure: a market that rewards low prices above all else, with no mechanism to value the reliability that low prices erode. Resilience is a public good — everyone benefits from essential drugs being reliably available — but public goods are chronically underprovided by markets that price only the product and not its dependable supply. No one is paid to keep the buffer stock, maintain the redundant facility, or invest in the quality upgrades that prevent shortages, so no one does, until the shortage arrives and the cost is paid instead by patients. The fragility is not an oversight in the system; it is the system working as designed.

What a shortage actually costs

The abstraction of "supply chain fragility" obscures the concrete human cost, which lands where these things usually land: on the patients least able to absorb it. When an essential drug runs short, treatment is delayed, rationed, or substituted with a less suitable alternative. Cancer patients have chemotherapy postponed or switched to second-choice regimens. Hospitals ration sterile injectables and spend clinician time managing scarcity that should have been spent on care. Errors become more likely as staff improvise around missing supplies. The harm is real, measurable, and borne by people who did nothing to cause it and cannot do anything to prevent it.

There is a compounding injustice in who bears this cost. The drugs that go short are the essential, unglamorous ones used to treat serious conditions, so the people affected are often the sickest and most vulnerable — precisely those for whom a delayed or substituted treatment carries the gravest consequences. Meanwhile the savings that the low-price, low-resilience system generates are diffuse and invisible, spread thinly across the whole healthcare economy, while the costs are concentrated and severe. A system that quietly trades the reliability of life-saving medicine for marginal savings has made a bargain that no one would consciously choose, and it makes that bargain over and over because the people who would refuse it are not the ones who pay.

Why the cycle repeats

The final, maddening feature of drug shortages is their repetition. Each crisis prompts concern, inquiries, and promises, and then the attention fades and the underlying incentives, untouched, produce the next shortage. The reason is that fixing the problem properly would require changing the economics — paying more for reliability, valuing resilient supply as something worth funding, restructuring how essential generics are purchased so that dependable manufacturing is rewarded rather than punished. These are structural reforms, and structural reforms are hard, unglamorous, and easy to defer once the immediate crisis passes.

So the cycle continues. The shortages are treated as a series of unfortunate, unrelated events rather than as the recurring symptom of a fixed cause, which allows each one to be met with temporary measures rather than structural change. The market failure that produces them is never addressed because addressing it would mean confronting the uncomfortable truth that the low prices everyone celebrates are inseparable from the fragility everyone laments. Until the incentive to provide reliable supply is built into the system, the shortages will keep coming, predictable as clockwork, greeted each time with the same surprise. The problem is not mysterious. It is simply unfixed, because no one has been made responsible for fixing it.

Conclusion

Drug shortages are not accidents; they are the logical output of a market that prices essential generic medicines to the bone and, in doing so, strips the supply chain of the resilience that keeps them available. They strike the cheapest, most vital drugs precisely because those are the ones where reliability is unfunded, and they recur because no actor in the system has both the means and the incentive to invest in the redundancy that would prevent them. The cost falls on patients — the sickest, least able to absorb a delayed or rationed treatment — while the savings that create the fragility are spread invisibly across the system. Each shortage is met with surprise and temporary fixes, and each is followed by the next, because the structural cause is never touched. Naming that cause clearly — a market that values low prices and nothing else, in a domain where reliable supply is a matter of life and death — is the necessary first step toward treating drug shortages as what they are: not a run of bad luck, but a predictable failure that could be fixed if anyone were made responsible for fixing it.